A Phase II Study Of Trabectedin (ET-743, Yondelis RM) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas

Trial Profile

A Phase II Study Of Trabectedin (ET-743, Yondelis RM) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2014

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top